Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Poland Sp. z o.o.
Ul. Poleczki 35
Budynek A1
02-822 Warsaw
Poland
Phone: +48 22 351 51 00
Fax: +48 22 351 51 01
www.biogenidec.pl
Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the…
Michael Kern, director general of the German Chamber of Commerce in Poland, discusses the evolving economic and business landscape in Poland and the overall impact of German companies. Furthermore, he…
Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging…
Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to…
Michael Dembinski, chief advisor of the British Polish Chamber of Commerce, discusses the important role of the chamber in driving forward Polish clinical trials and the challenges in unlocking Poland’s…
Mirosław Wysocki, national consultant in the area of Public Health, professor at the National Institute of Public Health (NIH), the research institute responsible inter alia for health promotion and disease…
Monika Constant, director general of the French-Polish Chamber of Commerce in Poland (CCIFP), discusses the evolution of the two nations’ bilateral business relationship, the benefits of conducting business in Poland,…
Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care…
Bogna Cichowska-Duma, general director of the Employers’ Association of Innovative Pharmaceutical Companies (INFARMA), the voice of 28 leading innovative companies in Poland, discusses the challenges and opportunities for doing research…
Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims…
Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction…
Wojciech Kuta, editor-in-chief of Rynek Zdrowia, a leading Polish healthcare publication, discusses the interacting dynamics of the obstacles facing Polish healthcare, as the country aims to increase healthcare spending to…
See our Cookie Privacy Policy Here
